

<rss version="2.0"
     xmlns:content="http://purl.org/rss/1.0/modules/content/"
     xmlns:wfw="http://wellformedweb.org/CommentAPI/"
     xmlns:dc="http://purl.org/dc/elements/1.1/"
     xmlns:atom="http://www.w3.org/2005/Atom"
     xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
     xmlns:slash="http://purl.org/rss/1.0/modules/slash/">

    <channel>
        <title>PharmiWeb.com PwToday Stories</title>
        <atom:link href="https://www.pharmiweb.com/rss/pwtoday" rel="self" type="application/rss+xml" />
        <link>https://www.pharmiweb.com</link>
        <description>PharmiWeb.com | PWToday Stories about the Pharmaceutical industry</description>
        <lastBuildDate>Mon, 01 Jun 2026 12:20:01 +00:00</lastBuildDate>
        <language>en-GB</language>
        <sy:updatePeriod>hourly</sy:updatePeriod>
        <sy:updateFrequency>1</sy:updateFrequency>
                <item>
                    <title>Concept Life Sciences and OpenBench Launch Drug Discovery Partnership</title>
                    <link>https://www.pharmiweb.com/pwtoday-story/concept-life-sciences-and-openbench-launch-drug-discovery-partnership</link>
                    <pubDate>Thu, 21 May 2026 08:51:42 +00:00</pubDate>
                    <guid isPermaLink="false">233831</guid>
                    <description><![CDATA[Concept Life Sciences has partnered with OpenBench to expand access to success based drug discovery services for early stage biotechnology companies. The collaboration combines Concept Life Sciences’ integrated CRO expertise with OpenBench’s AI enabled virtual screening platform to help accelerate the identification of novel drug candidates.
The partnership is designed to reduce early discovery risk and lower upfront costs for biotech innovators by offering a model where clients pay for succe...]]></description>
                </item>
                <item>
                    <title>GSK partners with SBP Group to support bepirovirsen launch in China</title>
                    <link>https://www.pharmiweb.com/pwtoday-story/gsk-partners-with-sbp-group-to-support-bepirovirsen-launch-in-china</link>
                    <pubDate>Tue, 12 May 2026 08:09:45 +00:00</pubDate>
                    <guid isPermaLink="false">233123</guid>
                    <description><![CDATA[GSK has entered an exclusive strategic collaboration with Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing Pharmaceutical Group (CTTQ) to accelerate the launch of bepirovirsen in mainland China. The investigational therapy is currently under priority regulatory review in China as a potential first-in-class treatment for chronic hepatitis B (CHB). 
Under the agreement, CTTQ will oversee importation, distribution, hospital access and promotional activities for bepirovirsen across mainland...]]></description>
                </item>
                <item>
                    <title>UCB, Cancer Research UK and Cancer Research Horizons form oncology alliance</title>
                    <link>https://www.pharmiweb.com/pwtoday-story/ucb-cancer-research-uk-and-cancer-research-horizons-form-oncology-alliance</link>
                    <pubDate>Thu, 07 May 2026 08:36:43 +00:00</pubDate>
                    <guid isPermaLink="false">232916</guid>
                    <description><![CDATA[UCB, Cancer Research UK and Cancer Research Horizons have announced a new strategic alliance aimed at accelerating the development of novel cancer therapies. The collaboration will combine UCB’s expertise in antibody discovery and drug development with Cancer Research UK’s translational research capabilities and Cancer Research Horizons’ oncology innovation network.
The partnership is designed to speed the progression of promising oncology assets from early discovery through to clinical devel...]]></description>
                </item>
                <item>
                    <title>MSD (Merck) to acquire Terns Pharmaceuticals in USD 6.7 billion deal</title>
                    <link>https://www.pharmiweb.com/pwtoday-story/msd-merck-to-acquire-terns-pharmaceuticals-in-usd-67-billion-deal</link>
                    <pubDate>Wed, 06 May 2026 09:28:55 +00:00</pubDate>
                    <guid isPermaLink="false">232825</guid>
                    <description><![CDATA[MSD (Merck Sharp &amp;amp; Dohme)&amp;nbsp; has agreed to acquire Terns Pharmaceuticals in an all cash deal valued at approximately USD 6.7 billion, expanding its oncology and hematology pipeline. The acquisition gives Merck access to TERN 701, an investigational oral treatment for chronic myeloid leukemia currently in Phase 1 and 2 development. Merck said the programme has the potential to become a leading option for certain blood cancer patients and supports the company’s long term growth strategy...]]></description>
                </item>
                <item>
                    <title>UCB to acquire Candid Therapeutics</title>
                    <link>https://www.pharmiweb.com/pwtoday-story/ucb-to-acquire-candid-therapeutics</link>
                    <pubDate>Tue, 05 May 2026 10:25:47 +00:00</pubDate>
                    <guid isPermaLink="false">232711</guid>
                    <description><![CDATA[UCB, a global biopharmaceutical company, today (May 3rd) announced signing of a definitive agreement under which it would acquire Candid Therapeutics (Candid), a privately held clinical-stage biotechnology company redefining the treatment of autoimmune and inflammatory diseases through novel T-cell engagers (TCEs). This transaction supports UCB’s ambition to bring differentiated solutions to people with severe immune-mediated diseases by focusing on areas of high unmet need and it illustrates...]]></description>
                </item>
    </channel>
</rss>